A randomized multicenter non-inferiority phase III trial of chemoradiotherapy and local excision versus total mesorectal excision in T2–T3ab,N0,M0 rectal cancer (the TAUTEM study)

Dataset

DOI

According to international guidelines, the standard treatment of stage T2-T3ab,N0,M0 rectal cancer is total mesorectal excision (TME). The TAUTEM study is a multicenter phase III trial designed to assess an alternative treatment that preserves the rectum applying oncological non-inferiority criteria

Identifier
DOI	https://doi.org/10.34810/data1181
Related Identifier	IsCitedBy https://doi.org/10.1200/JCO.2022.40.16_suppl.3501
Related Identifier	IsCitedBy https://doi.org/10.1016/j.annonc.2022.09.160
Metadata Access	https://dataverse.csuc.cat/oai?verb=GetRecord&metadataPrefix=oai_datacite&identifier=doi:10.34810/data1181

Provenance
Creator	Serra Aracil, Xavier (ORCID: 0000-0003-0291-1900)
Publisher	CORA.Repositori de Dades de Recerca
Contributor	Serra-Aracil, Xavier; Fundació Institut d'Investigació i Innovació Parc Taulí
Publication Year	2024
Rights	CC BY-NC-SA 4.0; info:eu-repo/semantics/openAccess; http://creativecommons.org/licenses/by-nc-sa/4.0
OpenAccess	true
Contact	Serra-Aracil, Xavier (Institut Investigacio Innovacio Parc Tauli (I3PT))

Representation
Resource Type	Clinical data; Dataset
Format	text/plain; text/tab-separated-values
Size	4618; 15439; 95002
Version	1.1
Discipline	Life Sciences; Medicine

​​A randomized multicenter non-inferiority phase III trial of chemoradiotherapy and local excision versus total mesorectal excision in T2–T3ab,N0,M0 rectal cancer (the TAUTEM study)​

A randomized multicenter non-inferiority phase III trial of chemoradiotherapy and local excision versus total mesorectal excision in T2–T3ab,N0,M0 rectal cancer (the TAUTEM study)